Organovo Signs Distributor Deal After Positive Data For Bio-Printed Liver Tissue

Organovo Holdings Inc ONVO announced an exclusive distributor agreement with Cosmo Bio Co., Ltd. for its NovoView Preclinical Services in Japan, a day after it presented positive preclinical data of its 3D bio-printed human liver tissue when implanted into animal models.

Organovo said it saw evidence of stable production of key human liver proteins in the animal bloodstream and tissue staining for key human metabolic enzymes.

FDA

Organovo intends to submit an Investigational New Drug application to the U.S. Food and Drug Administration for its therapeutic liver tissue in three to five years. The company claims that total addressable market opportunity for these initial indication areas exceeds $3 billion in the United States.

Shares of Organovo closed Tuesday’s trading at $3.79. In the pre-market hours on Wednesday, the stock gained 3.43 percent to $3.92.